StockNews.com upgraded shares of Lipocine (NASDAQ:LPCN – Free Report) from a hold rating to a buy rating in a report published on Friday.
Lipocine Stock Up 1.5 %
Shares of NASDAQ:LPCN opened at $4.84 on Friday. The company has a market capitalization of $25.88 million, a price-to-earnings ratio of -2.83 and a beta of 1.21. The company has a 50 day moving average of $4.58 and a two-hundred day moving average of $5.52. Lipocine has a 52-week low of $2.31 and a 52-week high of $11.79.
Lipocine (NASDAQ:LPCN – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. The company had revenue of $0.09 million for the quarter. On average, equities analysts anticipate that Lipocine will post -0.92 earnings per share for the current year.
Institutional Investors Weigh In On Lipocine
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Featured Stories
- Five stocks we like better than Lipocine
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Stock Analyst Ratings and Canadian Analyst Ratings
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.